enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of “Buy” by Analysts

enGene Holdings Inc. (NASDAQ:ENGN) has received an average recommendation of “Buy” from the ten research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $25.22.

A number of research analysts recently weighed in on ENGN shares. UBS Group lowered shares of enGene from a “buy” rating to a “neutral” rating and dropped their price target for the company from $34.00 to $7.00 in a research report on Friday, February 14th. Morgan Stanley dropped their target price on shares of enGene from $37.00 to $34.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 11th. Piper Sandler began coverage on enGene in a report on Tuesday, February 18th. They issued an “overweight” rating and a $26.00 target price for the company. Raymond James assumed coverage on enGene in a research report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price target for the company. Finally, JMP Securities reissued a “market outperform” rating and issued a $18.00 price objective on shares of enGene in a research report on Monday, December 23rd.

Institutional Trading of enGene

A number of large investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC lifted its position in shares of enGene by 15.7% during the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock valued at $102,000 after buying an additional 2,080 shares during the last quarter. Vontobel Holding Ltd. bought a new stake in enGene in the 4th quarter valued at about $69,000. Jane Street Group LLC purchased a new stake in enGene during the fourth quarter valued at about $93,000. Toronto Dominion Bank bought a new position in enGene during the fourth quarter worth about $97,000. Finally, Corton Capital Inc. purchased a new position in shares of enGene in the fourth quarter worth about $157,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Stock Down 3.5 %

Shares of NASDAQ:ENGN opened at $5.21 on Friday. The business’s 50 day moving average is $6.29 and its 200 day moving average is $7.07. enGene has a 12-month low of $4.42 and a 12-month high of $18.40. The stock has a market cap of $265.59 million, a price-to-earnings ratio of -8.98 and a beta of -0.61. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. On average, sell-side analysts forecast that enGene will post -1.56 earnings per share for the current fiscal year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.